Table 3.
Factors associated with progression-free survival
| Characteristics | N | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | Adjusted HR | 95% CI | P | ||
| Age, years | |||||||
| <50 | 39 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| ≥50 | 89 | 1.540 | 0.958−2.477 | 0.075 | 1.377 | 0.850−2.232 | 0.194 |
| FIGO stage | |||||||
| III | 77 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| IV | 51 | 1.903 | 1.244−2.912 | 0.003 | 1.358 | 0.867−2.126 | 0.182 |
| Primary treatment strategy | |||||||
| PDS | 79 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| NAC | 49 | 2.098 | 1.373−3.206 | 0.001 | 2.103 | 1.321−3.348 | 0.002 |
| Residual tumor after PDS/IDS | |||||||
| Optimal debulking | 109 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| Suboptimal debulking | 19 | 1.515 | 0.867−2.648 | 0.145 | 1.587 | 0.879−2.865 | 0.126 |
| BRCA status | |||||||
| Wild-type | 77 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| Mutation | 51 | 0.484 | 0.310−0.755 | 0.001 | 0.502 | 0.318−0.795 | 0.003 |
Abbreviations: CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC neoadjuvant chemotherapy, IDS interval debulking surgery, HR hazard ratio, CI confidence interval, Ref reference